# Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

> **NCT04978012** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 48 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma
- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Fluzoparib and Camrelizumab

## Key facts

- **NCT ID:** NCT04978012
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978012, "Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04978012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*